EPCAM and neoplasm: While the authors showed that only a small percentage of EpCAM−/CD45− cells had KRAS mutant reads in RNA-seq data, this approach could potentially neglect tumor cell heterogeneity that could account for epithelial PDAC cells that have lost EpCAM expression.